US 11,918,560 B2
Serine protease inhibitor for treating coronavirus infection
Dror Ben-Asher, Tel-Aviv (IL); and Reza Fathi, Oradell, NJ (US)
Assigned to RedHill Biopharma Ltd., Tel-Aviv (IL)
Filed by RedHill Biopharma Ltd., Tel-Aviv (IL)
Filed on Jun. 10, 2021, as Appl. No. 17/344,430.
Application 17/344,430 is a continuation of application No. 17/195,333, filed on Mar. 8, 2021, granted, now 11,045,453.
Claims priority of provisional application 63/125,427, filed on Dec. 15, 2020.
Claims priority of provisional application 63/074,799, filed on Sep. 4, 2020.
Claims priority of provisional application 63/034,817, filed on Jun. 4, 2020.
Claims priority of provisional application 63/003,601, filed on Apr. 1, 2020.
Claims priority of provisional application 62/987,429, filed on Mar. 10, 2020.
Prior Publication US 2021/0299108 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/435 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/4409 (2006.01); A61M 31/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/435 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/4409 (2013.01); A61M 31/00 (2013.01); A61P 31/14 (2018.01)] 20 Claims
 
1. A method of treating a coronavirus infection comprising administering to a person in need thereof a composition comprising an effective amount of WX-671,

OG Complex Work Unit Chemistry
as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof.